1nhaler key facts
as of Oct 2026- Developer of a dry powder inhaler designed to assist with inhalable medications.
- 1nhaler is valued at approximately $13.8M as of Oct 2026 (last reported valuation).
- It has raised $4.5M; the latest was Later Stage VC ($1.9M) in Nov 2025.
- Notable investors include Scottish Enterprise, British Business Investments, Archangel Investors, Yusuf Hamied.
- Status: Privately Held (backing).
1nhaler's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·Watch 1nhaler: the Monday email on marks, rounds and moves
1nhaler funding rounds
No funding rounds for 1nhaler are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
1nhaler valuation
1nhaler's last reported valuation was $13.8 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
1nhaler investors
4 investors are on record for 1nhaler, including Scottish Enterprise, British Business Investments, Archangel Investors and Yusuf Hamied.
About 1nhaler
Developer of a dry powder inhaler designed to assist with inhalable medications. The company offers a breath-activated, low-cost disposable cardboard device that uses a breathable membrane to store the relevant drug within the device to avoid the issue of agglomeration and provide convenient single-dose inhalers, enabling customers to replace traditional inhalers with portable, distributable, and recyclable alternatives and access life-saving inhalable drugs.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2017
- Employees
- 5
- Website
- 1nhaler.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.